Table 2. Univariate Survival Analysis of OS and DFS in 68 patients with HCC.
| Variables | No. of cases | OS | DFS | ||||
| Mean±SE (month) | 95% CI | P a | Mean±SE (month) | 95% CI | P a | ||
| Gender | 0.476 | 0.403 | |||||
| Male | 57 | 39±5 | (30–48) | 31±5 | (22–40) | ||
| Female | 11 | 38±7 | (24–51) | 35±7 | (21–49) | ||
| Age(years) | 0.456 | 0.769 | |||||
| <65 | 44 | 38±5 | (28–48) | 33±5 | (22–43) | ||
| ≥65 | 24 | 38±6 | (27–50) | 32±6 | (20–44) | ||
| Viral status | 0.182 | 0.359 | |||||
| Hepatitis virus B | 49 | 37±5 | (28–47) | 30±5 | (21–39) | ||
| Hepatitis virus C | 12 | 40±10 | (20–60) | 35±11 | (14–57) | ||
| Both hepatitis virus B and C | 2 | 19±10 | (0–37) | 9±4 | (2–15) | ||
| Non-B, Non-C | 5 | 62±11 | (40–83) | 54±11 | (33–76) | ||
| Tumor size | 0.665 | 0.749 | |||||
| <5 cm | 37 | 41±6 | (30–52) | 34±6 | (23–45) | ||
| ≥5 cm | 31 | 38±6 | (26–50) | 32±6 | (19–44) | ||
| portal vein invasion | <0.001 | <0.001 | |||||
| No | 49 | 51±5 | (41–61) | 43±5 | (33–53) | ||
| Yes | 19 | 12±1 | (10–15) | 7±1 | (5–10) | ||
| Histopathological differentiation | 0.003 | 0.005 | |||||
| WD | 20 | 57±8 | (41–73) | 47±8 | (32–62) | ||
| MD | 25 | 37±5 | (26–47) | 32±6 | (21–43) | ||
| PD | 23 | 23±5 | (13–32) | 16±5 | (6–26) | ||
| Serum AFP level | 0.233 | 0.208 | |||||
| <25 ng/ml | 35 | 45±6 | (33–57) | 38±6 | (26–49) | ||
| ≥25 ng/ml | 33 | 31±4 | (22–39) | 25±5 | (15–34) | ||
| TNM stage | <0.001 | <0.001 | |||||
| I–II | 23 | 73±7 | (60–86) | 64±7 | (51–77) | ||
| III–IV | 45 | 23±3 | (17–30) | 17±4 | (11–24) | ||
| LAPTM4B genotypes | <0.001 | <0.001 | |||||
| *1/1 | 22 | 75±6 | (64–86) | 66±6 | (55–78) | ||
| *1/2 | 35 | 27±4 | (18–35) | 21±5 | (12–30) | ||
| *2/2 | 11 | 11±1 | (10–12) | 4±0 | (4–5) | ||
LAPTM4B, Lysosomal protein transmembrane 4 beta; HCC, hepatocellular carcinoma; OS, overall survival; DFS, disease-free survival; a, Log-rank test.